Build Your Comparison

Side-by-side financial analysis
TOI logo
TOI
MCK logo
MCK
CAH logo
CAH
AIOT logo
AIOT
Try popular comparisons:

Stock Comparison

TOI vs MCK vs CAH vs AIOT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TOI
The Oncology Institute, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$5.41B
5Y Perf.+1054.3%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$94.25B
5Y Perf.+34.2%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$52.68B
5Y Perf.+127.7%
AIOT
PowerFleet, Inc.

Communication Equipment

TechnologyNASDAQ • US
Market Cap$574M
5Y Perf.-7.7%

TOI vs MCK vs CAH vs AIOT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TOI logoTOI
MCK logoMCK
CAH logoCAH
AIOT logoAIOT
IndustryMedical - Care FacilitiesMedical - DistributionMedical - DistributionCommunication Equipment
Market Cap$5.41B$94.25B$52.68B$574M
Revenue (TTM)$546M$403.43B$250.55B$436M
Net Income (TTM)$-44M$4.76B$1.56B$-32M
Gross Margin14.8%3.6%3.7%55.2%
Operating Margin-6.0%1.6%0.9%1.7%
Forward P/E17.7x20.8x
Total Debt$104M$8.61B$9.35B$287M
Cash & Equiv.$34M$3.98B$3.87B$49M

TOI vs MCK vs CAH vs AIOTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TOI
MCK
CAH
AIOT
StockJun 24Jun 26Return
The Oncology Instit… (TOI)1001154.3+1054.3%
McKesson Corporation (MCK)100134.2+34.2%
Cardinal Health, In… (CAH)100227.7+127.7%
PowerFleet, Inc. (AIOT)10092.3-7.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: TOI vs MCK vs CAH vs AIOT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. The Oncology Institute, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. AIOT also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇MCK emerged as the overall leader. Track its performance:
TOI
The Oncology Institute, Inc.
The Defensive Pick

TOI is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 1.95, current ratio 1.59x
  • Beta 1.95 vs AIOT's 2.71
  • +100.4% vs AIOT's -11.0%
Best for: sleep-well-at-night
MCK
McKesson Corporation
The Long-Run Compounder

MCK carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 337.8% 10Y total return vs CAH's 211.1%
  • Better valuation composite
  • 1.2% margin vs TOI's -8.0%
  • 5.7% ROA vs TOI's -26.5%, ROIC 254.1% vs -41.2%
Best for: long-term compounding
CAH
Cardinal Health, Inc.
The Lower-Volatility Pick

CAH lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
AIOT
PowerFleet, Inc.
The Income Pick

AIOT is the clearest fit if your priority is income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 2.71, yield 17.8%
  • Rev growth 66.3%, EPS growth 60.6%, 3Y rev CAGR 42.2%
  • Beta 2.71, yield 17.8%, current ratio 1.12x
  • 66.3% revenue growth vs CAH's -1.9%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthAIOT logoAIOT66.3% revenue growth vs CAH's -1.9%
ValueMCK logoMCKBetter valuation composite
Quality / MarginsMCK logoMCK1.2% margin vs TOI's -8.0%
Stability / SafetyTOI logoTOIBeta 1.95 vs AIOT's 2.71
DividendsAIOT logoAIOT17.8% yield, 1-year raise streak, vs CAH's 0.9%, (1 stock pays no dividend)
Momentum (1Y)TOI logoTOI+100.4% vs AIOT's -11.0%
Efficiency (ROA)MCK logoMCK5.7% ROA vs TOI's -26.5%, ROIC 254.1% vs -41.2%

TOI vs MCK vs CAH vs AIOT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TOIThe Oncology Institute, Inc.
FY 2025
Health Care, Patient Service
49.5%$229M
Fee For Service
32.1%$149M
Capitated Revenue
17.4%$80M
Clinical Research Trials And Other Revenue
1.0%$5M
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
AIOTPowerFleet, Inc.
FY 2024
Service
62.8%$84M
Product
37.2%$50M

TOI vs MCK vs CAH vs AIOT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGCAH

Income & Cash Flow (Last 12 Months)

AIOT leads this category, winning 3 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 925.9x AIOT's $436M. MCK is the more profitable business, keeping 1.2% of every revenue dollar as net income compared to TOI's -8.0%. On growth, AIOT holds the edge at +47.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTOI logoTOIThe Oncology Inst…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …AIOT logoAIOTPowerFleet, Inc.
RevenueTrailing 12 months$546M$403.4B$250.5B$436M
EBITDAEarnings before interest/tax-$26M$7.1B$3.2B$69M
Net IncomeAfter-tax profit-$44M$4.8B$1.6B-$32M
Free Cash FlowCash after capex-$26M$5.9B$4.4B$3M
Gross MarginGross profit ÷ Revenue+14.8%+3.6%+3.7%+55.2%
Operating MarginEBIT ÷ Revenue-6.0%+1.6%+0.9%+1.7%
Net MarginNet income ÷ Revenue-8.0%+1.2%+0.6%-7.4%
FCF MarginFCF ÷ Revenue-4.7%+1.5%+1.8%+0.6%
Rev. Growth (YoY)Latest quarter vs prior year+41.2%+6.0%+11.0%+47.4%
EPS Growth (YoY)Latest quarter vs prior year+90.5%+37.0%-19.5%-25.5%
AIOT leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MCK leads this category, winning 4 of 5 comparable metrics.

At 20.4x trailing earnings, MCK trades at a 41% valuation discount to CAH's 34.7x P/E. On an enterprise value basis, MCK's 13.8x EV/EBITDA is more attractive than AIOT's 51.2x.

MetricTOI logoTOIThe Oncology Inst…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …AIOT logoAIOTPowerFleet, Inc.
Market CapShares × price$5.4B$94.2B$52.7B$574M
Enterprise ValueMkt cap + debt − cash$5.5B$98.9B$58.1B$813M
Trailing P/EPrice ÷ TTM EPS-9.83x20.43x34.71x-9.81x
Forward P/EPrice ÷ next-FY EPS est.17.72x20.79x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple13.77x18.97x51.19x
Price / SalesMarket cap ÷ Revenue10.75x0.23x0.24x1.58x
Price / BookPrice ÷ Book value/share1.13x
Price / FCFMarket cap ÷ FCF16.48x28.47x
MCK leads this category, winning 4 of 5 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 4 of 7 comparable metrics.

On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs AIOT's 3/9, reflecting strong financial health.

MetricTOI logoTOIThe Oncology Inst…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …AIOT logoAIOTPowerFleet, Inc.
ROE (TTM)Return on equity-6.6%
ROA (TTM)Return on assets-26.5%+5.7%+2.8%-3.4%
ROICReturn on invested capital-41.2%+2.5%+33.8%-4.3%
ROCEReturn on capital employed-33.7%+44.8%+19.2%-5.1%
Piotroski ScoreFundamental quality 0–94763
Debt / EquityFinancial leverage0.64x
Net DebtTotal debt minus cash$70M$4.6B$5.5B$238M
Cash & Equiv.Liquid assets$34M$4.0B$3.9B$49M
Total DebtShort + long-term debt$104M$8.6B$9.3B$287M
Interest CoverageEBIT ÷ Interest expense-4.96x51.78x6.38x0.47x
MCK leads this category, winning 4 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

TOI leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $41,299 today (with dividends reinvested), compared to $5,257 for TOI. Over the past 12 months, TOI leads with a +100.4% total return vs AIOT's -11.0%. The 3-year compound annual growth rate (CAGR) favors TOI at 111.1% vs AIOT's -4.0% — a key indicator of consistent wealth creation.

MetricTOI logoTOIThe Oncology Inst…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …AIOT logoAIOTPowerFleet, Inc.
YTD ReturnYear-to-date+44.7%-4.6%+9.3%-19.6%
1-Year ReturnPast 12 months+100.4%+7.7%+40.7%-11.0%
3-Year ReturnCumulative with dividends+841.3%+100.5%+163.7%-11.5%
5-Year ReturnCumulative with dividends-47.4%+313.0%+300.9%-11.5%
10-Year ReturnCumulative with dividends-45.3%+337.8%+211.1%-11.5%
CAGR (3Y)Annualised 3-year return+111.1%+26.1%+38.2%-4.0%
TOI leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MCK and CAH each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a -0.10 beta — it tends to amplify market swings less than AIOT's 2.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAH currently trades 95.8% from its 52-week high vs AIOT's 71.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTOI logoTOIThe Oncology Inst…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …AIOT logoAIOTPowerFleet, Inc.
Beta (5Y)Sensitivity to S&P 5001.95x-0.10x-0.07x2.71x
52-Week HighHighest price in past year$5.58$999.00$233.60$5.88
52-Week LowLowest price in past year$2.02$637.00$137.75$2.77
% of 52W HighCurrent price vs 52-week peak+95.2%+78.5%+95.8%+71.8%
RSI (14)Momentum oscillator 0–10065.355.574.465.9
Avg Volume (50D)Average daily shares traded1.6M879K1.9M1.5M
Evenly matched — MCK and CAH each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CAH and AIOT each lead in 1 of 2 comparable metrics.

Analyst consensus: TOI as "Buy", MCK as "Buy", CAH as "Buy", AIOT as "Buy". Consensus price targets imply 89.6% upside for AIOT (target: $8) vs 13.2% for CAH (target: $253). For income investors, AIOT offers the higher dividend yield at 17.85% vs MCK's 0.39%.

MetricTOI logoTOIThe Oncology Inst…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …AIOT logoAIOTPowerFleet, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$8.00$994.86$253.38$8.00
# AnalystsCovering analysts531335
Dividend YieldAnnual dividend ÷ price+0.4%+0.9%+17.8%
Dividend StreakConsecutive years of raises18401
Dividend / ShareAnnual DPS$3.07$2.04$0.75
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.0%+1.5%+0.5%
Evenly matched — CAH and AIOT each lead in 1 of 2 comparable metrics.
Key Takeaway

MCK leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). AIOT leads in 1 (Income & Cash Flow). 2 tied.

Best OverallMcKesson Corporation (MCK)Leads 2 of 6 categories
Loading custom metrics...

TOI vs MCK vs CAH vs AIOT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TOI or MCK or CAH or AIOT a better buy right now?

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). McKesson Corporation (MCK) offers the better valuation at 20. 4x trailing P/E (17. 7x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TOI or MCK or CAH or AIOT?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 20.

4x versus Cardinal Health, Inc. at 34. 7x. On forward P/E, McKesson Corporation is actually cheaper at 17. 7x.

03

Which is the better long-term investment — TOI or MCK or CAH or AIOT?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +313.

0%, compared to -47. 4% for The Oncology Institute, Inc. (TOI). Over 10 years, the gap is even starker: MCK returned +337. 8% versus TOI's -45. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TOI or MCK or CAH or AIOT?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

10β versus PowerFleet, Inc. 's 2. 71β — meaning AIOT is approximately -2739% more volatile than MCK relative to the S&P 500.

05

Which is growing faster — TOI or MCK or CAH or AIOT?

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to 23. 9% for The Oncology Institute, Inc.. Over a 3-year CAGR, AIOT leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TOI or MCK or CAH or AIOT?

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus -14. 1% for PowerFleet, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 6% versus -7. 2% for TOI. At the gross margin level — before operating expenses — AIOT leads at 53. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TOI or MCK or CAH or AIOT more undervalued right now?

On forward earnings alone, McKesson Corporation (MCK) trades at 17.

7x forward P/E versus 20. 8x for Cardinal Health, Inc. — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AIOT: 89. 6% to $8. 00.

08

Which pays a better dividend — TOI or MCK or CAH or AIOT?

In this comparison, AIOT (17.

8% yield), CAH (0. 9% yield), MCK (0. 4% yield) pay a dividend. TOI does not pay a meaningful dividend and should not be held primarily for income.

09

Is TOI or MCK or CAH or AIOT better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 07), 0. 9% yield, +211. 1% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +211. 1%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TOI and MCK and CAH and AIOT?

These companies operate in different sectors (TOI (Healthcare) and MCK (Healthcare) and CAH (Healthcare) and AIOT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; MCK is a mid-cap quality compounder stock; CAH is a mid-cap quality compounder stock; AIOT is a small-cap income-oriented stock. CAH, AIOT pay a dividend while TOI, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.